An investigation for investors in NASDAQ:SRNE shares was announced over potential breaches of fiduciary duties by certain officers and directors at San Diego, CA based Sorrento Therapeutics.
Shares of Sorrento Therapeutics Inc (NASDAQ:SRNE) declined from as high as $23.51 per share to $4.50 per share in February 2016.
Investors who purchased shares of Sorrento Therapeutics Inc (NASDAQ:SRNE) and currently hold any of those NASDAQ:SRNE shares have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain Sorrento Therapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders.
Sorrento Therapeutics, Inc. is a biopharmaceutical company that is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Sorrento Therapeutics Inc reported that its annual Total Revenue rose from $0.46 million in 2013 to $4.59 million in 2015 while its Net Loss increased from $21.91 million in 2013 to $45.81 million in 2015.
Those who purchased NASDAQ:SRNE shares have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego